Navigation Links
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference
Date:11/13/2012

CASTLE ROCK, Colo., Nov. 13, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that it will present at the 9th Annual Lazard Capital Markets Healthcare Conference, held November 13-14, 2012, at the Pierre Hotel in New York City.  

Steve Lundy, President and CEO of AspenBio, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.Event:2012 Lazard Capital Markets Healthcare ConferenceDate: Wednesday, November 14, 2012 Time: 2:30 pm (Eastern Time) Location:Regency B room; Pierre Hotel, New York, NYAbout AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.aspenbiopharma.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AspenBio to Present at 2012 Aegis Healthcare Conference
2. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
6. Regulus to Present at the Lazard Capital Markets Healthcare Conference
7. Heptares to Present at BIO-Europe 2012
8. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
9. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Organovo To Present At Lazard Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Follow ... level of each type of cholesterol carrier or lipoprotein ... presence of excessive cholesterol levels in the body, especially ... condition to heart attack and other cardiovascular disorders. Cardiovascular ... therefore testing for cholesterol levels on a regular basis, ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... 2014 FemCap Inc., www.femcap.com  an innovator ... of a patent No: US, 8,795,248 B2 dated Aug. ... FDA clearance in the U.S., 510(K) K121857, medical device ... patent is related to its menstrual cup with a ... is releasing FemmyCycle Teen, a third menstrual cup to ...
(Date:9/30/2014)... 2014 Lyme Research Alliance ... disease research at universities, today announced the awarding of ... identification, treatment and cure for Lyme and other tick-borne ... most applications in its history—over 20 grant proposals—a 100 ... were pleased to receive so many solid applications from ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... 29 Dawson James Securities, a,full- service investment ... coverage on CryoCor, Inc. (Nasdaq: CRYO ) ... price target of $6.00. John M.,Putnam, Sr. VP-Medical ... CryoCor,s recently FDA-approved cryoablation,system for atrial flutter and ...
... Pharmaxis,(ASX: PXS, Nasdaq: PXSL) today announced that its ... of people with bronchiectasis has met its two,primary ... Data from the 362 subject study demonstrated ... 12 weeks of treatment with Bronchitol,as assessed by ...
... Fund is Largest and First of its Kind in ... support initiatives,that enhance patient safety and quality of care, ... million to fund new and innovative programs,at hospitals, health ... is the largest and first of its kind given ...
Cached Biology Technology:Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 2Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 3
(Date:9/29/2014)... at home should use ventilation when cooking with a ... after a new study showed an association between gas ... bronchitis. , "In homes where a gas stove was ... is higher than in homes where a gas stove ... professor in the College of Public Health and Human ...
(Date:9/29/2014)... get a bad rap, and understandably so. The grain-of-rice-sized ... of millions of acres in the Western U.S. and ... to popular belief, these pests may not be to ... recently swept through the region. Instead, weather and topography ... fires than these bark-boring beetles. , New research led ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
Breaking Biology News(10 mins):Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... Today, on behalf of the Association for Molecular Pathology ... US Food and Drug Administration,s (FDA) meeting on "Ultra ... to Assess Analytical Validity." As they begin developing their ... officials on many important considerations for evaluating analytical validity. ...
... Sea will promote fish stock recovery and increase fishermen,s incomes, ... York., In the North Sea up to 75 per cent ... result that many fisheries are now badly overfished. In comparison, ... and their fisheries are now some of the most prosperous ...
... LOS ALAMOS, New Mexico, June 22, 2011 Los Alamos ... 2011 R&D100 Awards. Recognized as the "Oscars of Invention" ... 100 proven technological advances of the past year. The ... specific nucleic acids, a spacer fluid for oil wells ...
Cached Biology News:AMP comments at FDA meeting on next-generation sequencing 2Discards ban 'will boost fisheries', says new research 2Los Alamos National Laboratory earns 3 R&D 100 Awards 2Los Alamos National Laboratory earns 3 R&D 100 Awards 3
... latest entry in the Biomek line. With an,up-to-date ... robustness, it can meet the needs of just ... either one or two pipetting pods. With its ... standard for flexible laboratory solutions to meet your ...
... The Biomek FX provides complete ... applications. With 96-, 384-, ... heads in either single or ... FX offers maximum speed and ...
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
Biology Products: